Who is sponsoring NCT00037648?

NCT00037648 is sponsored by Amgen.

What condition does NCT00037648 study?

NCT00037648 studies Juvenile Chronic Arthritis.

What drugs are being tested in NCT00037648?

Interventions: Anakinra, Placebo.

What is the status of NCT00037648?

NCT00037648 is currently COMPLETED.

Last reviewed 2009-11-25 · How we verify

A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis

NCT00037648 Phase 2 COMPLETED

The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Details

Lead sponsor	Amgen
Phase	Phase 2
Status	COMPLETED
Enrolment	86
Start date	2000-07
Completion	2003-11

Conditions

Juvenile Chronic Arthritis

Interventions

Anakinra
Placebo

Primary outcomes

The primary outcome of the study was to evaluate the safety of anakinra — 28 weeks